A Chinese clinical study reported donor-derived anti-CD19 CAR-T results in patients whose B-cell acute lymphoblastic leukemia relapsed after stem-cell transplant. The trial reported complete remissions in 13 of 14 patients, including most cases with extramedullary disease, highlighting a potentially strong efficacy signal in a hard-to-treat setting. Donor-derived approaches can offer manufacturing and timing advantages compared with fresh autologous products, but the key unknown remains durability and the broader safety profile in larger cohorts. Still, the observed remission rates suggest the strategy may overcome some resistance mechanisms seen after transplant failure. If the findings reproduce in further studies, donor-derived CAR-T could become a prominent option for post-transplant relapse, particularly where rapid control is needed to bridge to longer-term recovery.